Manufacturing
Localising production in Uzbekistan: what it delivers to a foreign manufacturer
Factor 1. Government procurement
Public procurement is a significant sales channel for a number of therapeutic groups. Locally manufactured products receive preferences in it, so localisation changes not only unit cost but access to the channel itself. For hospital-oriented products this is often the decisive argument.
Factor 2. The regulatory deadline
From 1 January 2027 GMP compliance becomes mandatory under Decree UP-137. For companies whose sites lack such confirmation, localising at a certified facility is a way to retain market presence. Certified capacity, however, is limited.
Factor 3. Economics
- No inbound logistics for finished products and none of the associated risks.
- Shorter lead times to the domestic market and less currency exposure along the chain.
- More flexible batch sizing against actual demand.
- Local packaging and labelling without additional shipping.
Factor 4. Regional market access
A site in Uzbekistan can serve as a base for supplies to CIS countries. The specific opportunities depend on each country's regulatory requirements and are assessed separately.
What to evaluate before deciding
- Market size for the product in Uzbekistan and the share of the hospital segment.
- Compatibility of the dosage form with the site's equipment.
- Regulatory route: new registration, recognition or variation.
- Availability of raw and packaging materials, including alternative suppliers.
- Timelines: technology transfer plus regulatory procedures.
- Minimum economically viable batch size.
About the site
Laxisam Pharmaceuticals — pharmaceutical manufacturer and marketing authorisation holder in Tashkent, Uzbekistan, operating since 1994. The site operates according to GMP principles. Request current quality documentation and its scope for the proposed project from Laxisam.
Frequently asked questions
- What does localisation deliver in public procurement?
- Locally manufactured products receive preferences, which affects access to the hospital procurement channel. For products with a high hospital share this is often decisive.
- Is localisation linked to the 2027 GMP requirement?
- Yes. From 1 January 2027 GMP compliance becomes mandatory, and moving production to a certified site is one way to retain market presence.
- Can products be supplied from Uzbekistan to other CIS countries?
- The site can serve as a base for regional supply, but specific opportunities depend on each country's regulatory requirements.
- How does a localisation project start?
- With a feasibility assessment: review of the dosage form, composition, equipment requirements and raw material availability.
- Which dosage forms can be produced?
- Dosage forms, batch sizes, available capacity and timelines are confirmed after a technical assessment. Send the formulation, planned volume, packaging requirements and target market for review.